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Numerous rheumatologic autoimmune diseases, among which rheumatoid arthritis, are chronic inflammatory diseases capable of
inducing multiple cumulative articular and extra-articular damage, if not properly treated. Nevertheless, benign conditions may,
similarly, exhibit arthritis as their major clinical finding, but with short-term duration instead, and evolve to spontaneous
resolution in a few days to weeks, without permanent articular damage. Such distinction—self-limited arthritis with no need of
immunosuppressive treatment or chronic arthritis at early stages?—represents one of the greatest challenges in clinical practice,
once many metabolic, endocrine, neoplastic, granulomatous, infectious diseases and other autoimmune conditions may mimic
rheumatoid arthritis. Indeed, the diagnosis of rheumatoid arthritis at early stages is a crucial step to a more effective mitigation
of the disease-related damage. As a prototype of chronic inflammatory autoimmune disease, rheumatoid arthritis has been
linked to oxidative stress, a condition in which the pool of reactive oxygen species increases over time, either by their
augmented production, the reduction in antioxidant defenses, or the combination of both, ultimately implying compromise in
the redox signaling. The exact mechanisms through which oxidative stress may contribute to the initiation and perpetuation of
local (in the articular milieu) and systemic inflammation in rheumatoid arthritis, particularly at early stages, still remain to be
determined. Furthermore, the role of antioxidants as therapeutic adjuvants in the control of disease activity seems to be
overlooked, as a little number of short studies addressing this issue is currently found. Thus, the present review focuses on the
binomial rheumatoid arthritis-oxidative stress, bringing insights into their pathophysiological relationships, as well as the
implications of potential diagnostic oxidative stress biomarkers and therapeutic interventions directed to the oxidative status in
patients with rheumatoid arthritis.
1. Introduction
Rheumatoid arthritis (RA), a systemic autoimmune disease
with a characteristic pattern of joint destruction, is far long
recognized as a clinical condition associated with potential
compromise through diverse fronts, with organ damage not
only restricted to the musculoskeletal system [1–5]. With
regard to the disease course along time, great efforts have
been made in recent years in order to differentiate early
stages of the disease from those not associated to autoimmu-
nity [1, 6, 7]. The importance of such distinction came to
light by the observation that the pathophysiological mecha-
nisms involved in the initiation and establishment of RA
change as the time goes by, with some inflammatory
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mediators predominantly present at the early clinical disease
and not markedly observed in advanced stages of joint dam-
age [8–10]. The comprehension of this mutable pattern of
effector cytokines in RA does have potential therapeutic
implications, drawing the concept of window of opportunity,
that is, the utmost opportune moment to therapeutically
intervene [4, 8], in order to block local and systemic inflam-
matory cascades, aiming to have better control of disease
activity and, consequently, better clinical outcomes [3, 6, 11].
Considering the well-recognized connection between
oxidative stress and chronic inflammation [12–15], the for-
mer also known as redox imbalance, described as a condition
in which the pool of reactive oxygen species (ROS) increases
over time, either by their augmented production, the reduc-
tion in antioxidant defenses, and/or the combination of both
[14, 16], ultimately leading to impaired redox signaling
and/or compromise in the control of molecular damage
[17], it becomes easy to admit the potential cross-talk
between oxidative stress and RA, as such autoimmune
disease characteristically represents an entity of chronic
systemic inflammation [5, 18, 19]. Despite this almost self-
explained interaction, very few studies were devoted to the
comprehension of the in-depth mechanisms through which
redox imbalance may contribute to the establishment of the
proinflammatory milieu observed in RA and vice versa, with
fewer studies focusing on the study of oxidative biomarkers
in such autoimmune arthritis [12, 19, 20].
In the context of differential diagnosis, however, many
metabolic, endocrine, neoplastic, granulomatous, infectious
diseases and other autoimmune conditions may mimic RA
[3, 8, 10], the reason why one might ask: how to say for sure
it is RA what is being talked about if, at early stages, too many
mimickers may challenge us? The hope for answering this
question seems to rest on the identification of biomarkers
and/or the development of properly validated clinical models
capable of predicting the risk of progression to chronic
arthritis in patients at early stages of a yet undifferentiated
arthritis [1, 6, 8, 21]. Thus, the present review focuses on
the binomial rheumatoid arthritis-oxidative stress, bringing
insights into their pathophysiological relationships, as well
as the implications of potential diagnostic oxidative stress
biomarkers and therapeutic interventions directed to the oxi-
dative status in patients with RA. The search for clinical trials
based on antioxidant complementary treatments in RA used
the combination of descriptors “Oxidative Stress AND Rheu-
matoid Arthritis AND Clinical Trial” in three different data-
bases, namely, CENTRAL, EMBASE, and PubMed. Figure 1
summarizes the sequence of selection till the final analysis.
2. The Binomial Rheumatoid Arthritis-
Oxidative Stress
2.1. Early Disease in Rheumatoid Arthritis: Earlier Than
First Thought. RA, a chronic inflammatory disease affect-
ing mainly the synovial tissue [4, 8, 9] with persistent
synovitis [22–24] and a destructive articular pattern [25],
occupies the top position in the list of systemic autoim-
mune diseases [4].
The concepts of disease duration for RA are not consen-
sual in the literature [7], but in general, early disease has been
referred to as that with duration of at least 3 months [1, 7]
and less than 12 months [25], once disease duration superior
to one year characterizes what has been called established RA
[4]. Also, in an attempt to reinforce the importance of
prompt diagnosis and establishment of directed pharmaco-
logical treatment as soon as possible, some studies go further
in such conceptual aspect and define what is called very early
arthritis [7, 8], a term that would be reserved to clinical pre-
sentations with no longer than 12 weeks of duration [7, 26].
Such cut-off point was defined by the observation that at 3
months, the disease pattern is already established: the pres-
ence of synovitis for 12 weeks increases the likelihood of
evolving to chronic inflammatory joint disease, so that
shorter durations are associated with better prognosis [7, 8]
(Figure 2). In line with the efforts to more adequately under-
stand the progression of the immunopathogenic pathways
along the disease course, a novel classification by stages has
been recently suggested: triggering phase, with individuals
genetically predisposed to RA exposed to diverse environ-
mental triggers; maturation phase, in individuals without
synovitis but positive for anticitrullinated protein antibodies
(ACPA); targeting phase, in individuals seropositive for
ACPA with arthralgia; and fulminant disease, characterized
by established RA [18].
Approximately one percent of the general population
carries the disease [23, 27, 28], and its concept of being a sys-
temic condition highlights the fact that the burden of RA,
when it comes to body damage, is not only restricted to joints
[4, 5, 24, 25]. Indeed, the systemic inflammatory milieu
observed in RA patients leads them to increased cardiovascu-
lar risk [4, 5, 25, 29], besides potential damage to different
organs, including, but not only restricted to, the eyes [30],
lungs [24, 31], heart [30, 32], small vessels [4], and skin
[30], ultimately implying higher probability of premature
death [21, 33, 34].
Considering that the articular compromise in RA may
last for decades, the idea that the early stages of the disease
would stand for periods as long as many months to years
could sound as a plausible concept [10], allowing the applica-
tion of the watch and wait policy, that is, waiting for initiating
pharmacological treatment only when no doubt about the
diagnosis of RA existed [8]. This conduct, however, does
not seem to be adequate, once recent cohort studies and
others have shown that the early stages of the disease are
actually earlier than first thought [6, 7, 9, 23, 24, 26], with
the need of prompt treatment with disease-modifying anti-
rheumatic drugs (DMARDs) as soon as the diagnosis is
made, considering the predictors of high risk for evolving
with chronic arthritis [6, 30].
The aforementioned definitions in the timeline of RA
have been recently emphasized because of the recognition,
in the last two decades, that the immunopathogenic path-
ways in the initial course of the disease differ from those
observed in advanced stages [9, 21–23, 25, 26]. And what is
more, in preclinical stages of RA, a systemic subclinical pro-
inflammatory milieu is already recognized [9, 25], with the
identification of circulating autoantibodies until 18 years
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before the clinical manifestations of the disease, reinforcing
the idea that the immune dysregulation in RA patients is trig-
gered even before the disease is clinically manifested [9, 24].
Thus, the clinically observed RA may not simply represent
a disease, but a spectrum of presentation of a syndrome
[30] with multiple interconnected pathogenic pathways,
which takes its place silently before it could be even dreamed
of [25].
2.2. Back in Time: What History Tells Us about the Binomial
Oxidative Stress-Rheumatoid Arthritis. Pathophysiologically,
RA is still not fully understood [20, 28, 35–37]. The first
references mentioning the term “rheumatoid arthritis” found
in the PubMed database come from 1876, represented by two
citations [31, 38]. Nevertheless, the journey for the compre-
hension towards the linkage between oxidative stress and
RA is much younger, dating back to approximately 30 years.
In an interesting study, Koster and colleagues demonstrated
lower concentrations of serum sulphydryl groups in RA
patients compared to healthy controls. Considering that
sulphydryl groups may act as scavengers of peroxides, such
finding, at that time, already pointed to concrete evidence
of oxidative stress in RA patients [39].
Ever since, different studies have focused on the oxidative
status as a potential contributor in the initiation and establish-
ment of a proinflammatory milieu in individuals with RA.
Currently, literature undoubtedly points to the oxidative
stress signature in the pathogenesis of RA [12, 13, 15, 19, 20,
40]. Oxidative stress is described as a deleterious condition
characterized by a negative balance in the pool of oxidative
molecules, favoring the predominance of prooxidants [14,
16], that is, ROS and reactive nitrogen species (RNS).
These species, mainly represented by nitric oxide (⋅NO)
[41–44], superoxide anion radical (⋅O2
-) [45], peroxynitrite
anion (ONOO-) [46, 47], hydroxyl (⋅OH) [48], lipoperox-
ide (LOO⋅) [14, 16], hydrogen peroxide (H2O2) [49, 50],
and hypochlorous acid (HClO) [51], are highly reactive
molecules generated during physiological cellular pro-
cesses, as well as under several pathological conditions
[9, 12, 14, 20, 47, 48, 51, 52].
Besides the potentially increased amounts of ROS/RNS in
situations of oxidative stress, antioxidants also act as
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Figure 1: Workflow through the different phases of the review.
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regulatory players, as they are substances or compounds
capable of scavenging ROS/RNS and, thus, inhibiting the
oxidation process in cells [16, 52]. Two different classes of
antioxidants exist, namely, the enzymatic and nonenzymatic
systems. The first type is mainly represented by superoxide
dismutase (SOD) [52–54], catalase (CAT) [55], glutathione
peroxidase (GPx) [56], glutathione reductase (GR) [57],
and thioredoxin reductase [58]. ⋅O2
- and H2O2 represent
the most produced ROS [16, 56], with the former scavenged
by SOD [52] and the latter by CAT [55], GPx [56], and
peroxiredoxins (PRX) [59]. The nonenzymatic antioxidant
system, in turn, gathers some vitamins (A, C, and E), β-car-
otene, and antioxidant minerals, such as copper, ferritin,
zinc, manganese, and selenium [16, 60].
In this regard, the use of oxidative stress biomarkers as a
promising additional alternative in assessing disease activity
and prognosis in RA patients has evolved, being recently
emphasized [4, 20]. Accordingly, a 2016 meta-analysis, by
evaluating clinical trials with RA individuals to study
oxidative biomarkers as adjuvants in monitoring disease pro-
gression, found a positive correlation between lipid peroxida-
tion (assessed by the serum levels of malondialdehyde
(MDA)) and disease activity (evaluated by the disease activity
score DAS-28), reinforcing the assumption that oxidative
stress and disease activity in RA move towards the same
direction. In addition, the authors highlight the potential
applicability of oxidative biomarkers not only for comple-
mentary assessing disease activity but also for prognostic
purposes [20].
During the preparation of the current review article,
among the 813 articles found in the PubMed database in
April 2019 for the combined descriptors “Rheumatoid
Arthritis AND Oxidative Stress”, in this amount included
192 review articles, only 29 clinical trials were found address-
ing oxidative stress as a potential source of measurable bio-
markers and as a therapeutic target in RA (Figure 1). Two
studies were only available as abstracts, because full texts
were published in Chinese (Figure 1). Such numbers evi-
dence the relative lack of clinical studies aiming at investigat-
ing the cross-talk between the binomial oxidative stress-
rheumatoid arthritis, and thus, the state of the art points to
oxidative stress as a broad field in the seek for biomarkers
and new complementary therapeutic interventions with
potential to be added to conventional treatment options cur-
rently available for RA.
2.3. Oxidative Stress and Local Inflammation: Where
Destruction Journey Begins. Oxidative stress configures a
Healthy synovial joint
Preclinical
stages
Very early RA ≤ 12
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Persistent
synovitis
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Clinical events
Systemic
subclinical pro-
inflammatory
milieu
Compact bone
Spongy bone
Synovial membrane
Joint cavity
(contains synovial fluid) 
Articular cartilage
Synovial fluid
Destructive articular
pattern
Early disease
3-12 months Established RA
Cartilage damage
Synovitis for 12 weeks 
Pain Swollenjoint
Joint
stiffness
Synovial oxidative stress
Pannus
Redox imbalance
Inflammation
Rheumatoid arthritis
Figure 2: Marching on towards joint destruction: the timeline of rheumatoid arthritis. Years or even decades before clinical disease,
rheumatoid arthritis individuals may already exhibit elevated levels of circulating autoantibodies in a systemic subclinical proinflammatory
milieu. As the intra-articular oxidative stress and local inflammatory mediators, either cellular or soluble ones, take their places in disease
progression, the clinical manifestations become apparent, manifested mainly by joint pain and swelling, with consequent inflammatory
morning stiffness. This occurrence characterizes the prototype of inflammatory arthritis, which if not properly treated, preferentially at
early stages, might evolve to permanent articular damage, with prominent joint destruction and disability. RA: rheumatoid arthritis.
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critical contributor in the initiation and maintenance of
pathogenic mechanisms observed in systemic inflammatory
conditions, including RA [12, 19, 29, 33, 34, 61, 62]. When
it comes to physiological conditions, the production and
clearance of ROS and RNS should be maintained, ideally, in
a dynamic balance, once they exert pleiotropic effects on
growth, differentiation, chemotaxis, and cell death [15],
being also crucial in the defense mechanisms against patho-
gens [14]. Under pathological conditions, however, such
molecules, produced at great rates by articular neutrophils,
monocytes, and macrophages [63], are capable of damaging
different cell structures, including DNA, carbohydrates, pro-
teins, and lipids [13, 14, 37, 61, 64], contributing to the estab-
lishment of oxidative stress (Figure 3). In this regard, the
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Figure 3: Cellular and molecular mechanisms of oxidative stress and inflammation in rheumatoid arthritis. Multidirectional
interconnections are seen in the cellular and molecular mechanisms involved in the initiation and progression of articular damage in
rheumatoid arthritis, so that oxidative stress may imply increased inflammation and vice versa, ultimately leading to a vicious cycle
through which the hallmark of rheumatoid arthritis, i.e., synovitis, becomes established. (1) Arrival of inflammatory cells in the synovium;
(2) establishment of synovitis; (3) soluble proinflammatory mediators produced by inflammatory cells; (4) direct effector mechanisms (cell
activation, transcription of proinflammatory genes); (5) persistent synovitis and irreversible articular damage. ACPA: anticitrullinated
protein antibodies; FLS: fibroblast-like synoviocyte; GM-CSF: granulocyte-macrophage colony-stimulating factor; H2O2: hydrogen
peroxide; IL-1: interleukin 1; IL-6: interleukin 6; NF-κB: nuclear factor-κB; MAPK: mitogen-activated protein kinase; RF: rheumatoid
factor; RNS: reactive nitrogen species; ROS: reactive oxygen species; TNF: tumor necrosis factor.
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ROS/RNS most commonly found in affected joints are repre-
sented by ⋅O2
-, H2O2,
⋅OH, NO⋅, ONOO-, HOCl, and LOO⋅,
besides the reactive compound hydrogen sulfide (H2S) [14,
16, 44, 48, 50].
Concerning the linkage between proinflammatory cells
and oxidative stress mediators, activated macrophages and
T cells in the synovium, for example, may induce the
production of ROS via tumor necrosis factor (TNF) and
interleukin (IL) 1 release [36], this way amplifying synovitis
[37]. And what is more, a positive feedback between
oxidative stress and inflammation is already recognized
(Figure 3), through which both players amplify the damaging
action of each other [12, 14, 65].
One of the most important pathways involved in the
pathogenesis of RA, defined as a high-grade inflammation
condition [4], is directly connected with oxidative stress.
In this respect, proinflammatory cytokines are responsible
for activating the mitogen-activated protein kinase
(MAPK), which, in turn, implies the subsequent activation
of nuclear factor-κB (NF-κB). Such molecule induces the
transcription of diverse genes associated with the mainte-
nance of inflammation [66]. Considering that ROS, mainly
H2O2 [15], may activate the NF-κB pathway, it becomes
evident that oxidative stress is associated with the molecu-
lar signaling dysregulation observed in the early phases of
RA [67]. Furthermore, NF-κB may not only imply the
augmented production of IL-1 and TNF-α but could also
be activated by these proinflammatory cytokines, thus
establishing a positive feedback in a self-activation process
with each other [14] (Figure 3).
In this direction, RA patients with active disease, for
example, present with increased levels of ROS and dimin-
ished antioxidant potential, ultimately resulting in worse oxi-
dative status for these individuals when compared to healthy
controls [13]. Consequently, a greater degree of lipid peroxi-
dation may be found [13, 15], either in the synovial fluid or in
blood samples from RA individuals [68, 69]. Accordingly,
serum levels of MDA, a marker of lipid peroxidation, have
been described as presenting positive correlation with proin-
flammatory cytokines in RA [28], with reactive oxygen
metabolites (ROM) in blood samples also found to be
increased in patients with RA and positively correlated with
disease activity [61]. In line with these observations, lower
levels of antioxidants are also found in serum and synovial
fluid of RA patients [70].
When it comes to the effects of oxidative stress on specific
cellular types, ROS may induce death of chondrocytes,
particularly contributing to the articular damage observed
in early stages of RA [15]. Furthermore, the immune dysreg-
ulation seen in autoreactive T lymphocytes may be related to
their exposure to an environment of oxidative stress [4]. In
addition, the proinflammatory intra-articular cascades may
be amplified by the direct production of ROS by local macro-
phages [13] and by the local production of ACPA [4], as both
rheumatoid factor (RF) and ACPA are locally produced by B
cells found in the synovial tissue [25] (Figure 3).
Besides the participation of chemical mediators, physical
stimuli could also contribute to the continuum of joint oxida-
tive stress, as the increased intra-articular pressure secondary
to inflammation may be responsible for chronic hypoxia,
augmenting the production of ROS in joints from RA indi-
viduals [4]. Of note, not only functional cell alterations are
observed in the context of oxidative stress, a fact that could
be illustrated by structural extracellular changes including
the oxidation of type II collagen in joints from RA patients
[15], as well as by the increased production of matrix metal-
loproteinases [66], resulting in extracellular oxidative dam-
age [15]. Of particular importance is the collagen oxidation
described above, as it is responsible for increasing immuno-
genicity of extracellular matrix, contributing to amplify the
loss of self-tolerance to extracellular components [14]
(Figure 3).
Equally interesting, at the intracellular microenviron-
ment, somatic mutations in p53 in fibroblast-like synovio-
cytes (FLS) induced by oxidative stress may contribute to
synovial hyperplasia and the consequent formation of
pannus [15], that is, the excessively proliferated synovial
membrane with invasive behavior rich in CD4+/T lym-
phocytes [71], directly contributing to cartilage destruction
and bone erosions [27, 69] and reinforcing the broad spec-
trum of oxidative damage in RA [13, 15].
2.4. Oxidative Stress and Systemic Inflammation: Far beyond
the Articular Damage. Chronic inflammation, a prominent
feature of RA, contributes to the increment in cardiovascular
risk in its carriers [33, 34], as the risk factors classically
described for cardiovascular morbimortality, namely, smok-
ing, hypertension, diabetes mellitus, obesity, and sedentary
lifestyle, do not completely explain the increased cardiovas-
cular risk observed in RA patients [29].
Twenty years ago, the similarities between RA and the
atherosclerotic disease were already described, with the
observation of augmented levels of TNF, metalloproteinases,
IL-6, C-reactive protein (CRP), and endothelin in both con-
ditions. The same was true for neoangiogenesis and the
expression of adhesion molecules, among which P-selectin,
E-selectin, intercellular adhesion molecule 1 (ICAM-1), and
vascular cell adhesion molecule (VCAM-1), strengthening
the link between those vascular and articular inflammatory
diseases [72]. These pathophysiological similarities point to
the observation that the inflammatory mechanisms observed
in RA may contribute to the establishment of endothelial
dysfunction in such individuals, facilitating the understand-
ing of the phenomenon of increased cardiovascular risk in
RA patients [73].
In the context of vascular damage, endothelial dysfunc-
tion in RA patients is largely described, either in macrocircu-
lation or in microcirculation, with reports of positive
correlation between disease activity and microvascular
dysfunction in early RA. Interestingly, such microvascular
dysfunction may be identified even in patients with disease
in remission, which evidences that, probably, there must exist
other contributors but disease activity alone implying micro-
vascular endothelial dysfunction in clinically controlled
patients [4]. Furthermore, reinforcing the association
between oxidative stress and inflammation in RA-related
vascular dysfunction, IL-1, a proinflammatory cytokine pres-
ent both at preclinical and chronic stages of RA [9], is capable
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of inducing oxidative stress, with consequent vascular dam-
age in RA individuals. In fact, in such patients, improved
endothelial function by the inhibition of the action of such
cytokine could be observed [32].
As a systemic inflammatory disease, RA may also affects
other tissues and organs through its extra-articular manifes-
tations, besides vascular beds reported above, as exemplified
by subcutaneous nodules and leg ulcerations, systemic vascu-
litis, pulmonary fibrosis, scleritis and episcleritis, valvular
heart disease and conduction abnormalities, and cervical
myelopathy, among others seen in diseased individuals [30].
3. Antioxidant Therapy in Rheumatoid Arthritis
Oxidative stress is a pivotal player in the aggravation of
chronic inflammatory joint disease. Both experimental
models and assessments in patients showed, in addition to
elevated ROS and lipid peroxidation formation, a decrease
in antioxidant defenses [13, 14, 60, 67]. In this sense, antiox-
idant therapy may possibly offer novel adjuvant/complemen-
tary treatment options aiming at better controlling disease
activity [37], as many patients do not achieve remission/low
disease activity with the currently available pharmacological
treatment [9].
The involvement of oxidative stress in the pathogenesis
of inflammatory diseases, such as RA, has been demonstrated
in several studies [20, 32, 67, 69, 74]. ROS and RNS are
important categories of molecules generated in living systems
for cellular metabolism. However, when such reactive species
reach concentrations above the upper limit of normal range,
they damage cellular components [13, 14, 64]. In this way,
therapies that decrease oxidants and/or increase antioxidants
are promising in the treatment of various oxidative stress-
related inflammatory diseases [37].
Several works showed different therapies as efficient com-
plementary alternatives in disease activity control (Table 1)
through antioxidant effects, with improvements observed in
many disease activity parameters, such as disease activity
score-28 joints (DAS-28), erythrocyte sedimentation rate
(ESR), health assessment questionnaire-disability index
(HAQ-DI), and visual analog scale (VAS). Among them are
N-acetylcysteine, used in other diseases due to its antioxidant
effect [37], synbiotic supplementation [62], pomegranate
extract [66], coenzyme Q10 [70] and sesamin supplementa-
tion [68], rectal insufflation of ozone [35], saline balneother-
apy [64], and laser acupuncture [69]. For all adjuvant
therapies already described in the literature to date, Table 1
shows the route of administration, dose, duration, and other
details from each selected study.
When considering the conventional treatments ade-
quately established for RA, infliximab, an anti-TNF agent,
induces beneficial changes in disease activity and also in
redox status, evidenced by both the increase in antioxidant
defenses and by the decrease in ROS production, through
the reduced myeloperoxidase activity and lipid peroxidation
[67]. Interestingly, RA patients with coronary artery disease
presented increased levels of interleukin-1β, protein
carbonyl, nitrotyrosine, and MDA than those without the
diagnosis of RA. Indeed, in these patients, the inhibition of
IL-1 activity by anakinra treatment (single injection 100mg,
SC) reduced the oxidative stress by the reduction of nitrotyr-
osine, MDA, and protein carbonyl [32]. Similarly, in another
study, single injection of anakinra (150mg SC) decreased
MDA, nitrotyrosine, IL-6, and endothelin-1, improving the
vascular and left ventricular function in RA patients [75].
Still considering the traditional treatments for RA, meth-
otrexate (MTX), a first-line DMARD in the pharmacological
management of RA [30], induced the secretion of IL-10, an
anti-inflammatory cytokine, inhibited the production of
⋅NO and increased ROS generation in active RA patients
[27]. For these findings, the authors suggest that the
decreased ⋅NO levels may contribute to cytokine homeosta-
sis, and the augmented ROS generation may be responsible
for MTX apoptotic effect on inflammatory cells, leading to
the beneficial action of such DMARD [71].
In addition to conventional pharmacological therapies in
the context of RA, other approaches have been described as
effective strategies to ameliorate clinical or laboratory param-
eters in RA patients, either in aspects directly associated to
articular compromise or in systemic manifestations related
to RA. As an example, in a noninvasive assessment of endo-
thelial function in RA patients, Flammer and colleagues
showed that the angiotensin-converting enzyme inhibition
by ramipril improved endothelium-dependent vasodilata-
tion, without changes on disease activity or proinflammatory
markers [73]. Similarly, Hermann and collaborators also
showed an improvement in endothelial function of RA
patients after simvastatin treatment during 4 weeks, with this
result associated to attenuation of oxidative stress, indicated
by a reduction in oxidized low-density lipoprotein (oxLDL)
levels and in the oxLDL/LDL ratio [76].
RA patients treated with antioxidant vitamins A, E, and C
along with conventional DMARDs for 12 weeks showed
decreased levels of MDA and increased concentrations of
thiols and reduced glutathione (GSH) and vitamin C concen-
trations in blood samples. These patients also showed
decreased Rheumatoid Arthritis Disease Activity Index
(RADAI), suggesting that the antioxidant therapy was effi-
cient in improving both the disease activity and the redox
profile in these patients [74]. On the other hand, the
increased consumption of antioxidant-rich foods during 3
months did not change the levels of plasma antioxidants
and urine MDA in RA individuals. Nevertheless, the plasma
levels of retinol presented an inverse correlation with the
ESR, DAS-28, and CRP; the vitamin C, a negative relation-
ship with ESR and the HAQ score; the levels of uric acid, in
turn, were inversely correlated with the thrombocyte count,
pointing to the association between serum uric acid levels
and the degree of inflammation in RA patients [77].
Supplementation therapy has been widely described
mainly due to its potential antioxidant effect. As a represen-
tative of this approach, pomegranate (Punica granatum L)
is rich in flavonoids, which are potent antioxidants [78]. Its
consumption reduced serum oxidative stress in healthy sub-
jects and in atherosclerotic mice [79], as well as in diabetic
patients [80]. In RA individuals, pomegranate extract supple-
mentation augmented the concentrations of GPx and
reduced the DAS-28 and serum oxidative status [63, 66]. In
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the same direction, sesamin supplementation decreased
serum levels of MDA and increased total antioxidant capac-
ity in RA patients [68]. As another successful complementary
therapy, the coenzyme Q10 supplementation, in addition to
conventional medications for RA, decreased serum MDA
and TNF-α levels [70].
Probiotic therapy has also been described in RA individ-
uals. Synbiotic capsule supplements with Lactobacillus aci-
dophilus, Lactobacillus casei, and Bifidobacterium bifidum,
for example, improved DAS-28 and VAS pain and increased
nitrite, an indirect marker of ⋅NO concentrations, and the
GSH in plasma [62]. However, probiotic supplementation
containing only Lactobacillus casei was not enough to induce
significant effect on oxidative stress indices and antioxidant
status in such patients [28]. Other different types of nonphar-
macological interventions have been proposed as alternative
complementary therapies for RA individuals, since clinical
and oxidative stress improvements were observed with such
approaches. In this regard, Wadley and collaborators [65]
demonstrated, in patients with RA, that the aerobic exercise
training during 3 months decreased the DAS-28 and the
levels of 3-nitrotyrosine, an oxidative stress biomarker. On
the other hand, oxidative stress was shown to be increased
in response to a single bout of moderate-intensity exercise
[65]. In addition, RA patients that performed a 12-session
saline balneotherapy in a thermal mineral water pool for
20min every day increased the nonenzymatic superoxide
radical scavenger activity (NSSA) levels, a fact that was
accompanied by a significant clinical improvement in terms
of patient global assessment [64]. Similarly, complementary
treatment with laser acupuncture 3 days/week during 4
weeks diminished oxidative stress and inflammation, amelio-
rated antioxidant status, reduced ESR values, and improved
disease activity (assessed by DAS-28) [69]. Lastly, rectal
insufflation of ozone associated with MTX increased the
MTX clinical response in RA patients, besides reducing oxi-
dative damage and increasing antioxidant system [35].
4. Concluding Remarks
Despite the well-recognized participation of oxidative stress
in the pathophysiology of RA, clinical studies devoted to
complementary therapies focusing on antioxidant
approaches are still scarce. To date, a modest number of trials
have shown potential beneficial effects of antioxidant thera-
pies on clinical and biochemical parameters in individuals
with RA, shedding light on the perspective of using similar
therapies for mitigating disease-related damage, in associa-
tion with conventional DMARDs. Considering that most of
the studies focusing on RA and antioxidant therapies
enrolled small numbers of participants with different study
designs and distinct methodologies, it becomes difficult to
immediately extrapolate their results to RA patients in
general, but they represent important research pointing
to potential therapeutic interventions to be assessed in
larger studies.
Finally, to which extent oxidative stress biomarkers may
be useful for early diagnosis of RA and management
decisions, for the assessment of disease activity and therapeu-
tic responses, as well as how these potential add-on
antioxidant-based treatments will contribute to better disease
activity control still hides somewhere. The promising find-
ings from recent research invite us to figure this conundrum
out, somehow.
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